Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) and Immunocore (NASDAQ:IMCR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Risk and Volatility
Xenetic Biosciences has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
Profitability
This table compares Xenetic Biosciences and Immunocore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xenetic Biosciences | -75.90% | -40.62% | -34.97% |
| Immunocore | -4.20% | -4.54% | -1.66% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
| Immunocore | 1 | 5 | 6 | 1 | 2.54 |
Immunocore has a consensus target price of $56.38, indicating a potential upside of 72.40%. Given Immunocore’s stronger consensus rating and higher possible upside, analysts clearly believe Immunocore is more favorable than Xenetic Biosciences.
Valuation and Earnings
This table compares Xenetic Biosciences and Immunocore”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xenetic Biosciences | $2.98 million | 3.01 | -$2.68 million | ($1.16) | -3.38 |
| Immunocore | $400.02 million | 4.21 | -$35.51 million | ($0.37) | -88.38 |
Xenetic Biosciences has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 7.6% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Immunocore beats Xenetic Biosciences on 12 of the 15 factors compared between the two stocks.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
